3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
59
Neoplasms
6
Neoplasm Metastasis
5
Melanoma
5
Carcinoma, Non-Small-Cell Lung
5
Colorectal Neoplasms
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Hereditary Sensory and Autonomic Neuropathies
3
Endometrial Neoplasms
3
Breast Diseases
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neuroblastoma
2
Multiple Endocrine Neoplasia Type 1
2
Lymphoma
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Teratoma
1
Stomach Neoplasms
1
Solid Tumors Harboring a BRAF V600 Mutation
1
Solid Tumors
1
Rhabdomyosarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteitis Deformans
1
Neoplasms, Germ Cell and Embryonal
1
Interventions
pembrolizumab
72
Cisplatin
57
Cetuximab
38
Fluorouracil
25
Nivolumab
21
Radiotherapy
20
Carboplatin
19
Paclitaxel
14
Docetaxel
11
Cyclophosphamide
9
Gefitinib
8
fludarabine
7
durvalumab
7
zalutumumab
6
atezolizumab
6
Drug Therapy
6
Bleomycin
6
epacadostat
5
cemiplimab
5
Radiotherapy, Intensity-Modulated
5
Pemetrexed
5
Ipilimumab
5
Gemcitabine
5
Afatinib
5
spartalizumab
4
Standard of Care
4
Radiation
4
Injections
4
Immune Checkpoint Inhibitors
4
Fibroblast Growth Factor 7
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Head and Neck Neoplasms
×
ribociclib
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled